---
title: "U.S. stock market update: Cyclacel Pharma down 7.32%"
description: "Cyclacel Pharma fell 7.32%; Replimune rose 90.80%, with a transaction volume of USD 1.292 billion; Sarepta Therapeutics rose 7.26%, with a transaction volume of USD 616 million; Alibaba's Lam Pharmace"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/250850137.md"
published_at: "2025-07-30T19:33:13.000Z"
---

# U.S. stock market update: Cyclacel Pharma down 7.32%

> Cyclacel Pharma fell 7.32%; Replimune rose 90.80%, with a transaction volume of USD 1.292 billion; Sarepta Therapeutics rose 7.26%, with a transaction volume of USD 616 million; Alibaba's Lam Pharmaceutical rose 2.92%, with a transaction volume of USD 517 million; AbbVie fell 1.28%, with a market capitalization of USD 333.6 billion

**U.S. Stock Market Midday Update**

Cyclacel Pharma fell 7.32%, with increased trading volume. Based on recent important news:

1.  On July 28, Liminatus Pharma announced a strategic expansion into the cryptocurrency and blockchain sectors, planning to raise $500 million for long-term investments, which increased market attention on the biopharmaceutical industry, leading to fluctuations in Cyclacel's stock price.
    
2.  On July 28, executives of CEL-SCI Corporation purchased common stock of the company, enhancing market confidence in the biopharmaceutical industry, affecting Cyclacel's stock price.
    
3.  On July 29, directors of CEL-SCI Corporation again purchased common stock of the company, further boosting market confidence, affecting Cyclacel's stock price.
    

**Stocks with High Trading Volume in the Industry**

Replimune rose 90.80%, with a trading volume of $1.292 billion. Based on recent important news:

1.  On July 30, Replimune's RP1 drug was unexpectedly rejected in the BLA application, but due to Prasad's departure, analysts believe the chances of accelerated approval for RP1 have greatly increased, causing the stock price to surge.
    
2.  On July 28, Replimune presented new analysis results of the RP1 and Nivolumab combination therapy at the ASCO annual meeting, leading to positive market outlook and driving the stock price up.
    
3.  On July 29, several law firms announced a class action lawsuit against Replimune; nevertheless, investor confidence in the company's future remained unaffected, and the stock price continued to rise.
    

Sarepta Therapeutics rose 7.26%, with increased trading volume. Based on recent important news:

1.  On July 29, the FDA recommended lifting the suspension on Sarepta's gene therapy Elevidys, causing the stock price to rise by 41.05%.
    
2.  On July 30, Barclays raised Sarepta's target price from $10 to $22.
    
3.  On July 29, JP Morgan and Oppenheimer upgraded Sarepta's rating, expecting Elevidys sales to reach $500 million to $600 million.
    

Alnylam Pharmaceuticals rose 2.92%, with increased trading volume. Based on recent important news:

1.  On June 26, Needham raised Alnylam Pharmaceuticals' target price from $320 to $377, reflecting market confidence in its RNAi therapy, driving the stock price up.
    
2.  On June 26, a block trade of Sinovac Biotech was discounted by 12.01%, indicating increased market attention on the pharmaceutical industry.
    
3.  On June 20, the stock of Zai Lab-B opened high at 73.8% in the dark market, reflecting positive market expectations for new drug launches **Stocks Ranked Among the Top by Market Capitalization in the Industry**
    

AbbVie fell 1.28%, with increased trading volume. Based on recent key news:

1.  On July 29, Eli Lilly announced that its drug Jaypirca successfully challenged AbbVie's Imbruvica in a Phase III clinical trial, putting pressure on AbbVie's stock price.
    
2.  On July 30, AbbVie released positive Phase III trial results for its drug Upadacitinib, but it failed to fully offset market concerns about competing drugs.
    
3.  On July 30, analysts expected AbbVie's upcoming quarterly earnings report might disappoint, further dragging down the stock price

### Related Stocks

- [CYCC.US - Cyclacel Pharma](https://longbridge.com/en/quote/CYCC.US.md)
- [BGMS.US - Bio Green Med Solution](https://longbridge.com/en/quote/BGMS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Kua Khai Loon，持有 10% 股份的股東，報告其在 Cyclacel Pharmaceuticals Inc 中出售了普通股 | Kua Khai Loon，Cyclacel Pharmaceuticals Inc 的 10% 股東，已報告出售該公司的普通股。完整的文件可通過提供的鏈接獲取。此消息由公共技術公司生成，僅供參考，不應被視為財務或法律建議。原始內容由 Cy | [Link](https://longbridge.com/en/news/256797793.md) |
| Cyclacel Pharmaceuticals Inc. 提交了關於 Kua Khai Loon 的初始實益擁有權聲明 | Cyclacel Pharmaceuticals Inc. 已提交初步的實益擁有權聲明，確認 Kua Khai Loon 為實益擁有者。該文件可以通過美國證券交易委員會的 EDGAR 系統訪問。此新聞簡報由 Public Technolog | [Link](https://longbridge.com/en/news/255589507.md) |
| Cyclacel Pharmaceuticals Inc. 執行認股權證交換，換取 559,395 股普通股 | Cyclacel Pharmaceuticals Inc. 於 2025 年 9 月 4 日與合格投資者簽署了一份認股權證交換協議，交換了 559,395 股 C 系列普通股認股權證。此次交換為非現金交易，所發行的股份未根據 1933 年證 | [Link](https://longbridge.com/en/news/256012877.md) |
| Cyclacel Pharmaceuticals Inc. 召開了虛擬特別股東會議 | Cyclacel Pharmaceuticals Inc. 於 2025 年 9 月 4 日召開了虛擬特別股東會議，會議上批准了多個提案。這些提案包括向 Fitters Parent 發行普通股，可能發行超過 20% 的流通股，以及修改公司 | [Link](https://longbridge.com/en/news/256168487.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.